Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). (Q41363639)
Jump to navigation
Jump to search
scientific article published on June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). |
scientific article published on June 2015 |
Statements
1 reference
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). (English)
1 reference
Daniel Podzamczer
1 reference
Bonaventura Clotet
1 reference
Jose M Miro
1 reference
Christian Manzardo
1 reference
Elena Ferrer
1 reference
Montserrat Loncà
1 reference
Alberto C Guardo
1 reference
Pere Domingo
1 reference
Anna Cruceta
1 reference
Iñaki Pérez
1 reference
Montserrat Plana
1 reference
Jose M Gatell
1 reference
Advanz-3 Study Group
1 reference
1 June 2015
1 reference
1 reference
Identifiers
1 reference